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Abstract 
This study correlates a LeadCare © II blood analyzer with Graphite Furnace Absorption 
Spectroscopy (GFAAS) and performs a comparison of the lead level results.  Subjects who 
currently occupied a lead containing building that was under construction were recruited.  The 
study consisted of 12 total participants.  One sample was collected from each subject via 
venipuncture.  The samples were then analyzed with both a LeadCare © II analyzer and also via 
Graphite Furnace Absorption Spectroscopy (GFAAS).  The sample mean for the GFAAS 
analysis was 1.56 µg/dL with a SD ± 1.93.  Many of the samples were reported at or below the 
limit of detection of 1.0 µg/dL.  The reportable range of the Lead © II device is 3.3 to 65 µg/dL 
with most of the results being reported <3.3 µg/dL.  Due to the analysis methods having different 
reportable ranges and most being below these measurable spectrum, it was considered illogical to 
make a comparison of measurements between these two devices.   
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
Acknowledgements 
I would like to begin by thanking my Advisor and Primary Investigator, Glenn Talaska, PhD, 
CIH, for his tremendous support, instruction and guidance throughout this study.  I would like to 
thank Susan Pinney, PhD for taking the time to analyze the study protocol and allowing us to 
work with her outstanding phlebotomist.  I would especially like to show my sincere thanks and 
gratitude to Victoria Straughn, for all of her dedication to this study and taking time to draw and 
collect the individual samples throughout the process.  Victoria was phenomenal with all of the 
subjects.  A big thanks to Peter Russell at Cincinnati Children’s for his coordination with the 
sample pick up and analysis.  Thank you to Andrew Maier, PhD, CIH, DABT and Nicholas 
Newman, DO, MS, FAAP for taking the time to review all documents and being available to 
address all of my questions. Finally, I would like to thank the Hamilton County Department of 
Health for donating the Leadcare© II to the Department of Environmental Health at the 
University of Cincinnati.   
 
 
 
 
 
 
 
 
 
 
 
v 
 
Table of Contents 
 
Abstract……………………………………………………………………………ii 
Acknowledgements……………………………………………………………….iv 
Table of Contents………………………………………………………………….v 
List of Tables and Figures………………………………………………………...vi 
Background………………………………………………………………………..1 
Results…………………………………………………………………………….16 
Discussion………………………………………………………………………...18 
Study Limitations…………………………………………………………………20 
Bibliography……………………………………………………………………....22 
 
 
 
 
 
 
 
 
 
 
 
 
vi 
 
List of Tables and Figures 
Tables: 
Table 1: Blood Lead Levels and Health Effects 
Table 2: QC Level 1 and 2 Mean and Standard Deviation 
Table 3: Study Demographics 
Figures: 
Figure 1: Chart of average blood level measured by the CCHMC/GFAAS method 
Figure 2: Distribution of blood lead level values from GFAAS analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
 
 
1 
 
Background 
Lead is found all throughout our environment-the air, the soil, the water, and even inside our 
own homes.  Most exposures to lead come from human activities including past uses of leaded 
gasoline, types of industrial facilities, and lead-based paint in homes.  Other household products 
containing lead include ceramics, pipe and plumbing materials, solders, gasoline, batteries, 
ammunition, and cosmetics1.  Lead is beneficial for many processes due to its density, durability, 
malleability, low melting point, long life-span, and ability to resist corrosion2.   
Some of the more common occupations that result in lead exposure include construction 
workers, steel welders, plumbers and pipe fitters, auto repairers, firing range instructors, and 
shipbuilders3.  Lead is most commonly found as a dust or fume in the workplace.  Routes of 
exposure for lead include breathing in lead dust or fumes and ingesting lead dust.  Lead is readily 
absorbed through inhalation, particularly lead fumes which are created by the condensation of 
gaseous lead.  Lead dust and fumes do not have an odor resulting in most employees not 
realizing that they are being exposed.4 Ingestion can occur by lead dust settling on food, water, 
clothes, and other objects.  It is particularly absorbed through the eyes, nose, and mouth.4   
The major sources of lead exposure in homes include paint, pipes, solders, water, batteries, and 
cosmetics.1 Lead exposure in homes remains a concern due to children being able to absorb more 
lead than adults and their brains and nervous systems being more sensitive to the damaging 
effects.1 Lead exposure in children has been known to lead to behavior and learning problems, 
lower IQ and hyperactivity, slowed growth, hearing problems, and anemia. Children also tend to 
touch more objects around their homes and then place their hands in their mouths creating a 
route of exposure.  This is a primary reason for ingestion being a significant route of exposure in 
young children.  This is especially dangerous in older homes that may contain lead based paint.  
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In fact, it was estimated that nearly 38 million households in the United States have lead based 
paint5.  In 2013, it was also discovered that approximately 75,760 children under the age of 6 had 
lead levels between (5-9 µg/dL).6  Lead exposure to children has become a major concern due to 
its ability to mimic one of the most important nutrients for children, Calcium.  Children have a 
desire for calcium in their younger years due to rapid bone growth.  With lead mimicking the 
absorption method of calcium, kids who are exposed could be effected because nearly 50% of 
the lead ingested is able to be absorbed by the body. 8 This is a significantly higher value in 
comparison to adults with only 10% of what they ingest being absorbed. 20      
Another major concern for lead is that usually no symptoms are associated with exposure and it 
is also capable of damaging nearly all systems and organs of the body. 6 The symptoms of lead 
exposure have been separated into both short and prolonged exposure.  The short term exposure 
health effects consist of abdominal pain, fatigue, headaches, loss of appetite, pain or tingling in 
the hands and feet, and weakness.  Many of these symptoms can be caused by other factors 
which usually results in people overlooking lead exposure.  The health effects from prolonged 
exposure involve abdominal pain, constipation, depression, being easily distracted, forgetfulness, 
irritability, and nausea.  Further symptoms could include high blood pressure, heart disease, 
kidney disease, reduced fertility, and complications with the systems of the human body 
particularly the nervous system.  As mentioned, lead is particularly dangerous to younger 
children causing neurological effects and mental retardation. 9 With the long half-life of lead, 
even a single exposure can lead to an internal dose that lasts for years.  The bottom line is that 
there is no safe lead level in the body.  The following table provides a representation of the 
health effects that could arise from different blood lead levels.   
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Lead Level Health Effect 
          >80 µg/dL serious, permanent health damage may occur, 
(extremely dangerous) 
Between 40 and 80 µg/dL serious health damage may be occuring, even 
if there are no symptoms (seriously elevated) 
Between 25 and 40 µg/dL regular exposure is occuring. There is some 
evidence of potential physiologic problems 
(elevated) 
Between 10 and 25 µg/dL lead is building up in the body and some 
exposure is occuring 
*Lead levels and effects were provided by the New York State Department of Health 16  
                       Table 1: Blood Lead Levels and Health Effects 
To protect the safety of employees in the workplace against substances such as lead that could be 
harmful to one’s health, agencies have established Occupational Exposure Limits (OELs) which 
enforce and recommend maximum exposure levels for a standard work day.  However, not all 
people will have the same health effects when exposed to similar levels.  There have been cases 
of employees becoming affected by a substance when the levels were below the OEL.   
The Occupational Safety and Health Administration has been established to assure safe and 
healthy working conditions for all working men and women by setting and enforcing standards 
through training, outreach, education, and assistance. 10 The OSHA regulations regarding lead 
include no worker being exposed to over 50 µg/m3 over a standard 8-hour workday.  Also, the 
action limit for lead exposure is set at 30 µg/m3 meaning if levels surpass this limit, continued 
monitoring and medical surveillance must be performed.  Employees must also undergo blood 
lead tests every six months. 11 The National Institute for Occupational Safety and Health 
(NIOSH) provided a recommended exposure limit (REL) of 50 µg/m3 over an 8 hour workday.12 
The American Conference of Governmental Hygienists (ACGIH) provides a threshold limit 
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value (TLV) and biological exposure index (BEI) of 50 µg/m3 and 30 µg/100 mL lead in the 
blood.13   
The appropriate blood lead level in adults has continued to remain a controversial topic.  
Fortunately, NIOSH has set a reference blood level of 10 µg/dL for adults.  NIOSH has obtained 
this reference level through continued research primarily by creating the Adult Blood Lead and 
Epidemiology Surveillance (ABLES).  ABLES began in 1987 and has continued to work to 
monitor laboratory-reported adult blood levels.  Due to current research associating decreased 
renal function at 5 µg/dL and an increased risk of hypertension at levels below 10 µg/dL, the 
Department of Health and Human Services has recommended that blood lead levels among all 
adults should be reduced to <10 µg/dL.14   
Trends overtime have indicated that one of the major contributors for elevated population lead 
levels has been leaded gasoline.  Studies have supported this statement through monitoring lead 
levels in different populations from the time it was beginning to be phased out in 1976 to present 
day.  A study by Pirkle et al. (1994) conducted a study from 1976 to 1991 monitored the blood 
lead levels of Mexican Americans who resided in the southwest part of the United States.  The 
findings of the study included the population aged from 1 to 74 having their mean blood levels 
decline by 78% (12.8 µg/dL to 2.8 µg/dL).  The study concludes that the major cause of this 
observed decline could be attributed to the removal of 99.8% of lead from gasoline. 21   
The current study was developed in 2013 when the Kettering Laboratory on the East Campus of 
the University of Cincinnati proposed to demolish the North wing.  The North wing has 
traditionally been home to the Department of Environmental Health (DEH) and had been since 
the late 1930’s when Dr. Robert A. Kehoe was able to receive financial support to construct the 
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laboratories.  The labs were initially used by Dr. Kehoe to work with toxicologists, industrial 
hygienists, physicians, chemical analysts, and engineers to evaluate and conduct experiments on 
occupational and environmental health problems.15   
Demolition of the North wing raises major concerns primarily due to the age of the building 
itself.  Many of the older materials during initial construction are still present inside the building.  
Specifically lead based paint, chemical residue, and lead containing pipes.  Also, experiments 
that involved mercury and beryllium were also conducted in the North wing of the building.   
The DEH faculty traditionally have offices in other parts of the building.  However, many 
laboratories, offices, and classrooms that are used by the department reside in the North wing.   
As previously stated, many construction materials contain lead due to its versatility.  With the 
North wing being completely demolished, the employees of Kettering and residents in the 
surrounding areas could be exposed by the lead dust particles that will be generated.  Exposure 
can occur when lead dusts and fumes are inhaled, or when lead is ingested via contaminated 
hands, food, water, cigarettes, or clothing.  Lead that enters the body is then released into the 
blood and distributed throughout the body.16   
Monitoring lead levels can become difficult due to the laboratory equipment required for 
analysis.  Monitoring levels via venipuncture and lab analysis are effective but create obstacles 
such as transportation and time to receive results.  Field portable blood lead analyzers have been 
created to provide a faster analysis of blood lead levels.  Instead of having to wait multiple days 
for the lab results, one can obtain blood lead levels of the individual within minutes.  Also, one 
does not have to store or transport samples which reduces both costs and the possibility of 
samples becoming contaminated.  The portable analyzers were initially developed for 
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measurements in children, however, using them in an occupational setting for adults has been 
evaluated as well 18.   
The initiative to develop an effective portable blood lead analyzer began in 1991 after the CDC 
provided a recommended blood level of 10 µg/dL for all children. 18 Research emphasized the 
analyzer using anodic stripping voltammetry (ASV).  The first instrument was created in 1997 
and was called the “LeadCare I”.  A second generation system with “lower regulatory 
requirements” was created in 2006 and called the “LeadCare II Blood Lead Test System” 19.  The 
benefit of the LeadCare © II is that anyone can perform analysis on it by following the manual 
instructions.  It has also been approved by the FDA for utilization in a non-laboratory setting 19.     
The Department of Environmental Health at the University of Cincinnati obtained a LeadCare © 
II device that was donated by the Hamilton County Department of Health.  In order to determine 
if the instrument would prove to be accurate in the field, multiple studies have been conducted 
that compared the LeadCare © II device to other analytical methods.  The first study conducted 
by Kuyat (2014) involved the comparison of blood lead results between the University of 
Cincinnati’s LeadCare © II analyzer to the Cincinnati Children’s Hospital Medical Center 
(CCHMC).  The objective of the study was to determine if LeadCare © II device would be 
applicable to monitoring employee blood lead levels during the demolition/renovation of the 
Kettering Laboratory North wing.  The study found that between the blood lead level results, the 
values were slightly different but not enough to be significant.  This suggests that one could 
consider using the LeadCare © II device to monitor the blood levels of employees.17    
The current study has been taken a step further with through comparison of a different method 
that CCHMC is using other than the LeadCare © I.  To further support the theory of being able 
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to use the LeadCare© II analyzer for employee blood lead analysis, the device was compared to 
the Graphite Furnace Atomic Absorption Spectroscopy (GFAAS) method.   All information 
provided here in the background emphasizes the health concerns associated with lead and the 
continuing problems that it has caused in the workplace.  Building demolition and renovation 
proves to be particularly dangerous when handling lead due to the possibility of dust exposure.  
If demolition or renovation must take place, one should ensure that proper measures are taken to 
enclose the area to prevent the particles from spreading.  Both the construction workers and all 
occupants in the area are at risk whenever these processes are performed.  According to a case 
study by the CDC in 1988, five workers developed lead poisoning after a bridge in 
Massachusetts was demolished.  The blood lead levels of the workers ranged from 67 to 160 
µg/dL.  Four out of the five workers developed symptoms that were consistent with lead 
poisoning and had to receive intravenous chelation therapy. 22    
  Even if proper control methods are taken, it is still important measure blood lead levels to 
monitor exposure levels.  The LeadCare © II device would serve as an efficient and quick 
method to monitor these levels for both the construction workers and occupants during the 
demolition/renovation process at the Kettering Laboratory.  
Methods 
Recruitment 
All material and methodology of this study were annually reviewed and approved by the 
University of Cincinnati’s Institutional Review Board.  This study undergoes annual review 
because it has been ongoing (IRB approval number 2014-0763) in an effort to analyze blood 
levels during the demolition of the north wing of Kettering Laboratories.  The participants 
contacted were involved in the previous study “Validation of Lead Care © II Portable Blood 
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Lead Analyzer” (Kuyat, 2014).  Participants in the previous study were required to be adult 
(18+) employees in the Department of Environmental Health (DEH).  The study did not allow 
any pregnant women.  All contact was made with the participants via email and office visits 
where the study was able to be reviewed and consents were collected.  All participants also filled 
out a preliminary questionnaire used to determine possible lead exposures other than the building 
demolition.  Each participant was assigned an identification number to assist in organizing all 
samples and results.  Once employees had agreed to participate, emails were exchanged to 
determine times of availability to collect the samples.   
Venous Blood Sampling  
All participant blood samples were taken by a certified phlebotomist who was an employee of 
the University of Cincinnati.  Approximately 3 milliliters (mL) were collected from each subject 
in a K2 ethylenediaminetetraacetic acid (EDTA) lead free tube with a tan cap.  One sample was 
collected from each participant in February and March of 2015.  All samples were collected in an 
unoccupied office on 2nd floor of the Kettering Building in the Environmental Health 
Department.  Standard procedures were followed for taking venous blood samples.  The area of 
the arm (cubital fossa) was wiped down with an alcohol swipe before a 21 gauge butterfly needle 
was used to puncture the vein.  Each subject was asked to verify their date of birth for 
identification purposes.  Each sample was given a specific I.D. and placed into a styrofoam 
cooler with ice packs.  Dates and times of the samples were also documented onto a research 
processing log sheet provided by CCHMC.  One copy was sent with the samples to CCHMC and 
other copies were made for the phlebotomist and study coordinator.  Once all samples were taken 
for the specific date, CCHMC was then contacted where a pick-up was coordinated.  Once 
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analyzed by CCHMC, the samples were then returned to the Biological Monitoring laboratory in 
the Kettering Building.     
Storage for Specimen 
The protocol stated that the blood samples were to be stored at approximately 50-90 degrees 
Fahrenheit and should be analyzed on the LeadCare © II device within 24 hours of being 
collected.  If refrigerated, the samples can be analyzed within 7 days.7 
LeadCare © II ASV Analysis 
The way that the LeadCare © II conducts analysis is through a process known as Anodic 
Stripping Voltammetry (ASV).  The process begins with the blood sample being mixed with the 
LeadCare Treatment Reagant which lyses the red blood cells (RBCs) causing the lead in the 
RBC wall to be released.  A sensor within the device then has a negative potential applied to it 
which allows for accumulation of the lead atoms on the test electrode.  This potential during this 
is rapidly reversed to release the lead ions.  The current that produced from the previous step is 
directly proportional to the concentration of lead in the sample.  A curve is created from 
measuring the current (microAmps) on the y-axis and the potential (mV) on the x-axis.  The area 
underneath this curve is then utilized to calculate the qualitative blood lead result.   
The LeadCare © II analyzer kit consisted of: 48 blood lead sensors, 48 LeadCare treatment 
reagent tubes, 50 LeadCare II heparinized capillary tubes and plungers, 50 LeadCare II droppers,  
a level 1 and level 2 control, calibration button, package insert, labels, and worksheets to record 
the data.  To ensure valid results, all equipment must be used before the provided expiration date.  
The specific kit used would not expire until April of 2016.  The LeadCare © II had a recordable 
range of 3.3-65.0 µg/dl with any value under 3.3 being reported as “Low” and any above 65.0 as 
“High”.  The device allowed the blood samples to be collected either via a finger prick and 
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drawing the blood through a capillary tube or drawing a venous sample.  The venous drawing 
method was used throughout the duration of this study.   
Prior to analysis, lab attire such as safety goggles, nitrile gloves, and a lab coat had to be worn at 
all times.  All supplies used during the analysis were sterilized with all cleaning equipment being 
kept away from the lead analysis device.  During the analysis, all worksheets were immediately 
filled out to ensure accurate results.  All reagent and test tubes were placed in a holder to prevent 
any spills or contamination.   
LeadCare © II Device Setup/Calibration 
Before the device was placed onto the Biomonitoring lab bench, the entire area was wiped down 
to prevent the machine from becoming polluted.  The analyzer needed to be plugged into an 
outlet and the lever on the back needed to be turned to the “ON” position.  As soon as the light 
on the main screen came on, a message reading “Please calibrate analyzer with button” was 
displayed.  The yellow calibration was found in the provided LeadCare © II kit.  On the front of 
the button, a specific QC Lot number was provided.  When the button was placed onto the 
reader, it was held down until the machine beeped.  A lot number was then provided on the 
device screen where it was verified that it matched the lot number on the yellow button.  The 
specific message read “Prepare sample use sensor lot XXXXX or recalibrate then insert sensor”.  
If the lot numbers matched up, then the LeadCare © II was ready for analysis. 
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Quality Control Tests 
To ensure the LeadCare © II results are precise; two levels of quality control (QC) tests were 
performed both before and after a set of blood samples were analyzed.  On the blood testing 
system data sheet they were labeled as “Level 1” and “Level 2” with a section where the lead 
level results were recorded.  Each QC was designated a target lead value range that the result was 
required to meet when analyzed to ensure accuracy.  The QC tests were treated and prepared as if 
it were an actual blood sample. The sample preparation method can be found below.  According 
to the Clinical Laboratory Improvement Amendments (CLIA) guidelines, controls should be run 
for each new lot, each new shipment of materials, any new operator, monthly to check on storage 
conditions, and when any other problems are identified.  Both the level 1 and 2 solutions were 
provided in the LeadCare © II test kit.  During each QC test, the level 1 control was performed 
first followed by the level 2.  Both of the controls were required to be mixed before being using 
with the cap being placed on an uncontaminated surface.  Once the results were obtained, the 
level was compared to the provided target range.  The target range for level 1 was 7.5 +/-3.0 
µg/dl and 24.8+/-4.0 µg/dl for level 2.  The target ranges were found on the labels of the 
appropriate level tubes.  Blood samples were not to be analyzed if any of the controls did not 
meet the acceptable range.  If the range was not met, operators were to call the LeadCare © II 
support line to troubleshoot the present issue.  The means and standard deviations of both QC 
levels that were obtained during the analysis are provided in table 2 below.  
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 QC Level 1 (µg/dL) QC Level 2 (µg/dL) 
Target Range 7.5 ±3.0 24.8±4.0 
Mean 6.6 23.6 
Standard Deviation 0.82 0.93 
 
Table 2. QC Levels 1 and 2 Mean and Standard Deviation 
Preparing the Samples 
Sample preparation began with a clean treatment reagent tube being labeled with the same 
sample ID that was assigned during the blood drawing.  The tubes were labeled by writing the 
number on stickers that were provided in the LeadCare © II test kit.  Once the cap of the reagent 
tube was removed, it was placed onto a clean surface and the tube was placed into a holder.  It 
was crucial that the inside of the cap did not touch anything in order to avoid contamination.  
Before being mixed with the reagent, the blood sample in the EDTA tube was introverted 
approximately ten times to mix the specimen.  Once mixed, the cap from the EDTA tube was 
removed and placed onto a clean surface.  A capillary tube from the test kit was then inserted 
horizontally into the EDTA tube to draw up approximately 50 µL of blood.  This was measured 
with a black line on the capillary tube.  The blood sample tube was then placed back into the tube 
holder with the cap placed back on.  Any excess blood in the area was cleaned up with the 
provided Kimwipes.  The capillary tube was then analyzed to ensure that it was filled all the way 
and did not have any bubbles or contaminants.  The full capillary tube was then placed into the 
treatment reagent where a plunger from the test kit was the placed at the top of the capillary tube 
and pressed down.  The operator was required to push the plunger all the way down to ensure 
that the entire 50 µL was dispensed into the reagent tube.  The reagent tube cap was then 
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replaced and the tube was introverted approximately ten times.  Once the contents in the reagent 
tube turned brown, the test sample was ready for analysis.  The capillary tube, Kimwipe, plunger, 
and any other material contaminated with blood were soaked in bleach water and then discarded 
into a biohazard waste container.   
Analyzing the Sample 
Once the sample was prepared, a sensor from the sensor container was removed with the lid to 
the container being immediately closed.  The sensor was grabbed at the end without the black 
bars.  The sensor was then inserted completely into the analyzer on the front of the device with 
the black bars facing up.  The operator had to check that the sensor was under the sensor guides 
and sat correctly on the analyzer deck.  This was done by hearing a “beep” and seeing the 
following message on the display screen: 
 
“ADD SAMPLE 
TO X ON SENSOR 
SENSOR LOT XXXXX” 
Both the sensor lot number on the display and the sensor lot number on the sensor container 
should have matched.  The sample mixture was then made sure that it as being used at room 
temperature and was also uniformly mixed.  The cap from the reagent treatment tube was then 
removed and placed onto a clean surface.  A transfer dropper was then taken from the test kit and 
placed into the reagent tube.  In order to draw up the sample with the dropper, the walls were 
squeezed and then released when the tip was placed into the sample.  The dropper was able to 
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draw up approximately ½ of the sample.  The dropper was then removed from the reagent tube 
with the dropper tip being placed on the “X” of the sensor.  The dropper walls were then 
squeezed to release the sample onto sensor.  The analyzer would then beep when enough of the 
sample was dropped.  After the beep, the 180 second (3 minute) countdown would begin on the 
display screen.  The message on the screen read: “TESTING, XXX SECONDS TO GO”.  The 
analyzer would beep again once the time was up and the results were presented on the display 
screen in µg/dL.  The official message of the displayed results read:  
“RECORD TEST RESULT 
XX µG/dL Pb 
THEN REMOVE SENSOR  
                                                           SENSOR LOT XXXXX” 
 
  The results were immediately recorded onto the “Blood Lead Testing System Data Sheet”.  The 
sensor was then removed from the analyzer which cleared the display screen making the machine 
ready for the next sample.  All contaminated materials such as the sensor, reagent tube, and 
dropper were placed into bleach water and then discarded into a biohazard waste container.  This 
procedure was repeated for every blood sample that was taken.  When the analyzer produced a 
level result as “Low”, this was interpreted as the blood lead level being lower than 3.3 µg/dL and 
the result was recorded as “<3.3 µg/dL”.  Any “High” display meant that the blood lead level 
was “>65 µg/dL” and further laboratory tests needed to be conducted.  Once all samples were 
analyzed and the necessary data was recorded, the analyzer was switched to “OFF”.  The EDTA 
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tubes containing the blood samples were placed into a biohazard packet and properly stored in 
the biological monitoring refrigerator.   
CCHMC Analysis, GFAAS  
CCHMC used a GFAAS device to conduct the blood lead analysis.  The specific machine that 
conducted the analysis was the PinAAcle 900T atomic absorption spectrometer with an AS 900 
furnace autosampler.  This method has proved to be both cost effective and also allows for 
detection limits that are under the blood-lead standards.  The blood analyzed had to be collected 
within 24 hours and stored in EDTA lead free tubes.  The venous blood samples were sent to 
CCHMC the day of collection to meet these criteria.  All samples were prepared by following the 
procedures provided in the PinAAcle 900T © User’s Guide.  The GFAAS method had an 
Analytical Measurement Range (AMR) of 1.0 to 60 µg/dL.  Samples below this range were 
reported as <1.0 µg/dL and samples above were reported as >60.0 µg/dL.  There are many ways 
to deal with non-detects, for the purpose of this study, any sample that was reported below the 
range were reported as 1.0 µg/dL for the statistical analysis.    
 
Providing Results to Subjects 
Results were provided on a CCHMC portal (CareEvolve) that was username and password 
protected.  Results were presented as a pdf which simply stated the date the samples were 
received along with the blood levels that were measured in mcg/dL.  The pdf copy with the 
results was then emailed to participants individually along with a letter stating the NIOSH 
reference blood levels for adults.   
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Results 
Demographics 
The study consisted of a total of 12 participants who had previously participated in a study done 
Kuyat (2014) validating the Lead Care © II Portable Blood Analyzer.  The mean age of the study 
population was 51.25 years (SD ± 16.72).  The preliminary questionnaire provided to this 
population resulted in approximately 33.3% living in a home that contained lead pipes or brass 
and copper pipes that were soldered with lead.  Also, 8.3% of the population currently resided in 
homes that contained lead based paint.  Finally, 8.3% of the participated in lead containing 
hobbies.  (Table 2).  
Characteristic/Demographic                                                                                                                       n=12 
Age (mean years ± SD)                                                                                                                          51.25 ±16.72 
Visited countries still using lead gasoline in past 2 years (% yes)                                                              0 
Involved in any research using lead (% yes)                                                                                                  0 
Home contains lead based paint (% yes)                                                                                                      8.3                                                                                  
Home contains lead pipes or brass and copper pipes soldered with lead (% yes)                               33.3 
Spouse has occupational exposure to lead (% yes)                                                                                      0 
Involved with hobbies that may contain lead (pottery, jewelry, shooting, etc.) (% yes)                      8.3 
Decant wine into leaded (crystal) glass (% yes)                                                                                             0 
Current smoker (% yes)                                                                                                                                      0       
 
 
Table 3: Study Demographics/Questionnaire Results 
 
LeadCare © II Analysis Results  
The venous blood samples were analyzed with the LeadCare © II Analyzer on March 3, March 
11, and April 16 of 2015.   Samples were analyzed as soon as they were returned by CCHMC.  
The reportable range of the device is 3.3 to 65 µg/dL.  From the LeadCare © II, all values were 
recorded as being under 3.3 µg/dL or “Low” with the exception of ID number 004 producing a 
value of 7.7 µg/dL. 
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CCHMC Results, GFAAS 
Venous blood samples were collected on 2/20/15, 3/4/15, and 3/31/15.  Multiple collection dates 
had to be used due to scheduling conflicts with the subjects.  No complications with the blood 
collections were experienced which resulted in all being included in the final data set.  CCHMC 
samples from the GFAAS analyzer ranged from 1.0 to 7.4 µg/dL.   This resulted in a sample 
mean of 1.56 µg/dL ± 1.93.  All samples were sent to the CCHMC lab the day of collection to 
ensure accurate results.   
 
Figure 1. Chart of average blood level measured by CCHMC/GFAAS method  
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Figure 2.  Distribution of Blood Level Values from GFAAS Analysis 
Results indicate that the overall levels had a low sample mean in comparison to the range.  This 
argument is strengthened by the distribution chart portrayed in figure 2 as a majority of the blood 
lead results were at or below 1.0 µg/dL. 
With I.D. #004 having a lead level above the “Low” range for both measuring devices, a 
comparison was able to be made between the two.  For the LeadCare © II analyzer, the recorded 
value was 7.7 µg/dL and 7.4 µg/dL for the GFAAS method.  As shown, these values are very 
similar but not exact.  
Discussion 
The overall method involved comparing a LeadCare © II analyzer to the Graphite Furnace 
Atomic Absorption method.  The reportable range at the lower end of the devices is 3.3 µg/dL 
for the LeadCare © II and 1.0 µg/dL for GFAAS.  The blood samples analyzed by the LeadCare 
92%
8%
Distribution of Blood Lead Results
% ≥ 1.0 mcg/dL
% 7.4 mcg/dL
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© II were mostly reported as <3.3 µg/dL which made it difficult to compare to the GFAAS 
method.  Most of the samples were also recorded as 1.0 µg/dL or even lower for GFAAS which 
did not allow for any comparison.  The exception came with sample ID #004 which had a 7.7 
µg/dL level from the LeadCare © II and a 7.4 µg/dL level for GFAAS.  Even here with a 
comparable value one can see that the recordable levels are not exact.  This small difference does 
not raise a great concern due to it being within the error of the device.  Both values were also 
close enough together that if medical attention was required, the treatment methods would be 
similar.  However, the accuracy of the measurements could decrease as the lead levels increase 
raising concern for true values and clinical applications.  Some of the samples were analyzed by 
the LeadCare © II device up to two weeks after collection which could have contributed to 
variation in the results.   
Storage of the samples could have also led to differences within the results.  According to the 
protocol, samples were required to be stored at precisely 50-90 degrees Fahrenheit and should 
have been analyzed on the LeadCare © II within 24 hours of collection.  If this was not 
practiced, the blood could have also been mixed with the reagent and analyzed within 48 hours 
or could have also been refrigerated and analyzed within 1 week.  A number of the samples were 
not able to be analyzed by the LeadCare © device within the 48 hours or one week time frame 
due to the lack of available reagent during the day of collection.   All samples were immediately 
stored into coolers with ice packs and transported to the CCHMC Laboratories immediately after 
collection.  CCHMC then stored the samples in their labs based on GFAAS requirements so 
these results were not affected.  The samples were then returned to Kettering Laboratory within 5 
business days.  All samples were refrigerated until they were able to be analyzed with the 
LeadCare © II device.   
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Due to only one set of samples being collected, it was difficult to determine if levels between the 
LeadCare © II device and the GFAAS method differed.  However, it was known that no blood 
level was recorded above the NIOSH REL of 10 µg/dL for adults.  A majority of the participants 
were right at or even below the lower level detection limit of the GFAAS at 1.0 µg/dL.  For the 
subject with a recorded level of 7.4 µg/dL, the direct source for this level was not determined.  
However, when the results were reviewed, the subject did explain that they currently reside in an 
older home and have frequently been making home improvements to the basement area.  If the 
basement area had lead containing material, this could be a possible source of exposure.  The 
subject was informed on how to take the proper precautionary steps and to stay updated on their 
blood lead levels.   
Study Limitations 
The most noticeable limitation of the study deals with the small sample size of only 12 
participants.  Only a total of twelve subjects were able to participate.  Having a larger population 
would have strengthened the data by providing more results and leading to a better correlation.  
Also, only taking one sample made it difficult to notice any trends in the data.  At least two 
samples should have been taken from subjects at different times to notice any increases or 
decreases in the data.  Many of the subjects had very low lead exposure levels which made the 
exposure analysis difficult.  Our lead analyzer is only capable of detecting levels at 3.3 µg/dL or 
above.  Most subjects had exposure levels below this value.  It would have improved the overall 
comparison by comparing subjects who had higher lead exposure levels preferably above this 
range.  Even most of the GFAAS results were measured at 1.4 µg/dL or lower.  Studies in the 
past have reported the reporting accuracy decreasing as the levels have increased.  The sample 
storage methods used did not follow the exact LeadCare © II storage protocol which could have 
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affected the final results.  Storing the samples according to the LeadCare © II requirements could 
have increased the overall accuracy of the readings.  
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